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Analysis of Binding of KIR3DS1*014 to HLA Suggests
Distinct Evolutionary History of KIR3DS1
Geraldine M. O’Connor,* Eriko Yamada,* Andy Rampersaud,* Rasmi Thomas,†,‡
Mary Carrington,†,‡ and Daniel W. McVicar*
NK cell activity is regulated by the integration of positive and negative signals. One important source of these signals for human NK
cells is the killer Ig-like receptor (KIR) family, which includes both members that transduce positive and those that generate neg-
ative signals. KIR3DL1 inhibits NK cell activity upon engagement by its ligand HLA-Bw4. The highly homologous KIR3DS1 is
an activating receptor, which is implicated in the outcome of a variety of pathological situations. However, unlike KIR3DL1, di-
rect binding of KIR3DS1+ cells to HLA has not been demonstrated. We analyzed four key amino acid differences bet-
ween KIR3DL1*01502 and KIR3DS1*013 to determine their role in KIR binding to HLA. Single substitutions of these re-
sidues dramatically reduced binding by KIR3DL1. In the reciprocal experiment, we found that the rare KIR3DS1 allotype
KIR3DS1*014 binds HLA-Bw4 even though it differs from KIR3DS1*013 at only one of these positions (position 138). This
reactivity was unexpectedly dependent on residues at other variable positions, as HLA-Bw4 binding was lost in receptors with
KIR3DL1-like residues at both positions 199 and 138. These data provide the first evidence, to our knowledge, for the direct
binding of KIR3DS1+ cells to HLA-Bw4 and highlight the key role for position 138 in determining ligand specificity of KIR3DS1.
They also reveal that KIR3DS1 reactivity and specificity is dictated by complex interactions between the residues in this region,
suggesting a unique functional evolution of KIR3DS1 within the activating KIR family. The Journal of Immunology, 2011, 187:
2162–2171.
T
he killer Ig-like receptor (KIR) family of NK receptors
consists of 14 members including receptors with both
inhibitory and activating potential (1). This family shows
a high degree of variation among populations, including varia-
tion in gene content, at the level of allelic polymorphism and
in the frequency and level of expression (2–4). Several of the
KIRs are known to bind to HLA class I molecules. KIR2DL1
and KIR2DL2/3 recognize HLA-C2 and -C1, respectively (5),
KIR3DL2 recognizes A*3 and A*11 allotypes (6), KIR2DL4 is
reported to bind to HLA-G (7), and KIR3DL1 recognizes HLA-A
or -B molecules expressing the Bw4 epitope (8). Activating
members of the KIR family, which show a high degree of se-
quence similarity to inhibitory members in the extracellular por-
tion, also bind to HLA, albeit with much lower affinity (9–11).
Recognition of HLA-Bw4 by KIR3DL1 allotypes is well char-
acterized, with sequence variation in the KIR3DL1 molecule, the
Bw4 molecule, and the sequence of peptide presented by the Bw4
molecule all influencing the interaction (12–15). There is also
growing evidence that KIR3DS1 may recognize HLA-Bw4. Sev-
eral genetic studies have correlated the presence of both KIR3DS1
and HLA-Bw4 with the outcome of disease (16). In particular in
HIV infection, it has been shown that the epistatic interaction of
KIR3DS1 and a subgroup of Bw4 carrying isoleucine at position
80 (Bw4-80I) delays progression to AIDS, reducing viral load
early as well as leading to a reduction in opportunistic infections
later in disease (17, 18). Functional evidence to support the in-
teraction of KIR3DS1 and HLA-Bw4, at least in the context of
HIV infection, comes from the report that KIR3DS1+ NK cells can
suppress HIV replication and lyse HIV+ target cells in a Bw4-
dependent manner (19). However, several attempts to characterize
the direct interaction of KIR3DS1 with Bw4 have been un-
successful—traditional Bw4+ target cell lines are not killed in
a KIR3DS1-dependent manner, and HLA-Bw4 tetramers do not
bind to KIR3DS1-expressing cells, even those tetramers that
present HIV-derived peptides (13, 20, 21).
The highly polymorphic KIR3DL1 gene locus is unique in the
KIR family in encoding both inhibitory (KIR3DL1) and activating
(KIR3DS1) allotypes. The 3D KIRs contain three extracellular Ig
domains termed D0 (membrane distal), D1, and D2 (membrane
proximal). Each of these domains is encoded by a separate exon,
exons 3, 4, and 5, respectively of the KIR3DL1 gene (22). The D1
and D2 domains of KIR3DL1 are homologous to the two Ig
domains of type I 2D KIRs (2DL1, 2, and 3), which contain a D1
and D2 but have a pseudoexon in place of exon 3. Type II 2D
KIRs (2DL4 and 2DL5) contain a D0 and D2 configuration. The
structure of the interaction of type I 2D KIRs with their HLA-C
ligands has been resolved and shown to be dependent on residues
from both D1 and D2 (23). Although no structure of a 3D KIR
either alone or in association with HLA has been resolved, a se-
quence comparison with the D1 and D2 domains of KIR3DL1
suggests that many of the predicted residues for 2D KIR are
preserved in the apparent interaction of KIR3DL1 with Bw4 (23).
The role of D0 is even less well defined, but this domain has been
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shown to be necessary in the binding of KIR3DL1 to HLA-
B*5101 (24). A recent model of the interaction of KIR3DL1 with
HLA-Bw4 proposes that D0 combines with D1 and D2 to form the
binding interface, with D0 making direct contact with the HLA
molecule (25).
Allotypic polymorphism of KIR3DL1 leads to variation in the
cell surface staining phenotypewith two specific anti-KIR3DL1 Ab
clones: DX9 and Z27. Initially, this was described as some allo-
types (including *005) giving a low-intensity staining pattern with
both Abs, whereas others (including *01502) give a high-intensity
pattern (26). However, as more allotypes have been described, it
has become clear that different allotypes show a broad range of Ab
staining levels. Evidence suggests that these differences are a re-
flection of the level of receptor expressed at the cell surface rather
than variation in Ab affinity (27). In one extreme case, the com-
mon *004 allotype, which folds poorly, is completely retained
intracellularly (28). The KIR3DS1 allotype is not recognized by
the DX9 clone but gives a very low intensity staining pattern with
Z27 (13, 29). Both DX9 and Z27 Abs can prevent binding of
KIR3DL1 to its Bw4 ligand, suggesting an overlap between the
Ab epitope and the HLA binding site.
KIR3DL1*054 is a recently described allotype of KIR3DL1,
which shows a pattern of amino acid substitutions in the D1 do-
main not seen in other inhibitory allotypes but present in the ac-
tivating KIR3DS1 (2). As the D1 domain is believed to contribute
to both the HLA binding face and the Ab recognition of these
molecules, we wished to address the role of the amino acids
shared between *054 and KIR3DS1 in the regulation of expres-
sion levels and in the recognition of HLA. Delineating the role of
these variable positions in the binding capacity of these receptors
will allow us to understand better the functional consequences
of KIR3DL1 polymorphism and, perhaps more importantly, will
provide insight into the specific requirements of KIR3DS1 for
HLA recognition, which to date has proved elusive.
Materials and Methods
Site-directed mutagenesis of KIR3DL1*01502 and
KIR3DS1*013
FLAG-tagged (N-terminal) KIR3DL1*01502 or KIR3DS1*013 (referred
to in this article as KIR3DS1) sequences were cloned into the pEF6V5-
HisTOPO vector. The transmembrane domain of KIR3DS1 was modified
to mirror that of KIR3DL1, negating the need for DAP12 association.
These sequences were then mutated using the QuikChange Site-Directed
Mutagenesis Kit (Stratagene) according to the manufacturer’s instructions
using the primers outlined in Table I.
To generate double mutants, mutated constructs were used as template
with primers for mutation of the second position as outlined above except
in the case of KIR3DS1 S163P + R166L where, due to the small distance
between the residues, a second set of primers was used. The full coding
sequence of the resulting plasmids was sequenced to confirm the mutations.
Analysis of KIR3DL1 expression on HEK293T cell lines
HEK293T cells were transfected as previously described (2) using plas-
mids containing full-length KIR3DL1*01502, KIR3DL1*054, KIR3DS1,
or mutants thereof. Expression of the KIR on transfected cells was ana-
lyzed by mAb staining using FITC-conjugated anti-FLAG (Sigma), PE-
conjugated anti-KIR3DL1 mAb clone DX9 (BioLegend), or clone Z27
(Beckman Coulter) and analyzed on a BD FACScan. All experiments in-
cluded staining with isotype control Abs to permit accurate positioning of
electronic gates for analysis of KIR3DL1 expression.
Analysis of HLA tetramer binding to KIR
The following tetramers were obtained through the National Institutes of
Health Tetramer Facility: B*0801 folded with FLKEQGGL (from HIV
nef), A*2402 folded with RYPLTFGW (from HIV nef), B*2705 folded
with SRHHAFLFR (from human aggrecan). B*5701 tetramer folded with
TSTLQEQIGW (from HIV gag) was a kind gift from Dr. Galit Alter
(Harvard Medical School, Boston, MA).
PE-conjugated HLA tetramers were incubated with transfected cell lines
for 30 min at 4˚C prior to washing and analysis on a BD FACScan. For
blocking experiments, cells were preincubated with unconjugated Z27 Ab
(10 mg/ml; Beckman Coulter) or mouse IgG1 (10 mg/ml; Sigma) for 10
min at 4˚C prior to staining with HLA tetramers. Integrity of the HLA
tetramers was verified by staining of a leukocyte Ig-like receptor subfamily
B member 1 (LILRB1)-transfected Ba/F3 cell line (data not shown).
KIR3DS1 reporter assay
Stable Jurkat cell lines expressing the extracellular domain of KIR3DS1
fused to the CD3 z-chain were used in an NFAT reporter assay as described
in Ref. 13. A reporter cell line for KIR3DS1*014 was generated by mu-
tating KIR3DS1 using the primer pair outlined in Table I and stimulated
with plate-bound Z27 Ab, the HLA class I deficient 721.221 cell line, or
HLA-B*5701 and HLA-B*5801 transfectants. Lysates were harvested, and
luciferase activity was measured using Promega’s Dual-Luciferase Re-
porter Assay System according to the manufacturer’s instructions. Lucif-
erase activity was normalized relative to unstimulated controls.
Results
Novel allelic variant of KIR3DL1 is poorly recognized by two
anti-3DL1 Abs despite maintained cell surface expression
The recently described KIR3DL1 allotype *054 is identical to the
highly expressed KIR3DL1*002 allotype except for the D1 do-
main, encoded by exon 4, where it is identical to KIR3DS1 (Fig.
1A). We have recently described that an HIV+ donor expressing
this rare allotype gives a very-low-intensity staining profile with
the DX9 Ab (2). This is possibly a reflection of reduced cell
surface expression, poor Ab affinity, or a consequence of viral
infection. To examine the cell surface expression and Ab affinity
of this KIR3DL1 allotype, we transfected HEK293T cells with
a construct consisting of the N-terminal FLAG-tagged *054 se-
quence. These cells were then stained with the anti-KIR3DL1 Abs
DX9 and Z27 and with anti-FLAG and compared with the pro-
file observed for another highly expressed KIR3DL1 allotype,
*01502, which has an additional variation at position 238 (Fig.
1A). The intensity of FLAG staining observed with the *054 con-
struct was comparable with that seen with the highly expressed
*01502 allotype confirming that the *054 allotype is well ex-
pressed at the cell surface (Fig. 1B, 1C). However, staining with
both Z27 and DX9 Abs was much dimmer than that seen with the
*01502 allotype, indicating that although both these Abs recog-
nize *054, they do so with reduced affinity. Thus, whereas vari-
ation in Ab staining for other allotypes of KIR3DL1 has been
ascribed to variation in cell surface expression, in the case of *054
reduced intensity of Ab staining is a reflection of reduced affinity
of both anti-3DL1 Abs for this allotype.
The recognition of KIR3DS1 by Z27 also results in a very low-
intensity staining pattern, whereas this allotype is not recognized
by DX9. Although it has been suggested that this is due to re-
duced Ab recognition, and not low expression of KIR3DS1, this
has not been formally addressed. To examine this, we compared
the intensity of FLAG staining of HEK293T cells transfected with
FLAG-tagged KIR3DS1 and KIR3DL1*01502 constructs. We
found no difference in the level of FLAG staining seen (Fig. 1D),
proving that these two receptors are expressed at a similar level
at the cell surface and implicating poor recognition of KIR3DS1
by Z27 in the observed low-intensity staining.
D1 residues differentially contribute to the DX9 and Z27
epitope
We next examined the role of the D1 amino acid residues in
controlling Ab affinity by mutating these amino acid residues in
*01502 to the corresponding amino acid found in *054 and 3DS1
using the primers outlined in Table I. Protein levels were titrated
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by transfection of HEK293T cells with increasing concentration
of DNA. Mutation of *01502 at a single residue 138 (glycine to
tryptophan, G138W) dramatically reduces recognition by both
DX9 and Z27 Abs (Fig. 2A), implicating this residue in the epi-
tope recognized by both Ab clones. The intensity of staining was
still greater than that seen with the *054 allotype suggesting that
while position 138 plays an important role in the formation of the
binding face, position 163, 166, or 238 also contributes to the
binding. Indeed, the combined mutation of residues 163 and 166
also caused a reduction in the affinity of both Abs for *01502 (data
not shown). When we examined the role of 163 and 166 in-
dividually, we found that mutation of 166 had a profound effect on
the recognition by DX9 but did not appear to contribute sub-
stantially to the Z27 epitope (Fig. 2B). Single mutation of the
residue at position 163 did not influence binding of either Ab. All
mutant constructs were carefully analyzed for evidence of in-
tracellular retention/variation in levels of cell surface expression
using anti-FLAG Ab. We did not see any consistent difference
relative to *01502. To reduce the noise due to slight variations in
transfection efficiency, we normalized DX9 and Z27 binding in-
tensity relative to the levels of FLAG staining observed. This ratio
gives a reflection of the Ab affinity without influence from slight
variations in the level of receptor expression.
As mutation of *01502 at residues 138, 166, and 163+166 re-
sults in reduced Ab recognition, we wished to examine the role
of these amino acids in the binding face of KIR3DS1. These
positions were altered in KIR3DS1 to express the residues found
in inhibitory KIR3DL1 allotypes. We observed differences in Ab
recognition by DX9 and Z27 Abs (Fig. 2C), in the absence of any
change in the degree of cell surface expression. Mutation of res-
idue 138 from tryptophan to the glycine residue, which is highly
conserved across all KIR receptors (apart from KIR3DS1), results
in increased recognition by the Z27 Ab but did not confer rec-
ognition by the DX9 Ab. This suggests that this amino acid is an
important determinant of the weak reactivity of Z27 seen for
3DS1, but reversion of this position to the common KIR3DL1
residue is not sufficient to allow DX9 recognition. Together with
the dramatic loss of DX9 reactivity in the reciprocal mutation of
*01502 (*01502 G138W, Fig. 2A), these data suggest that whereas
the presence of glycine at position 138 is necessary for strong
DX9 recognition, it is not sufficient. In contrast, substitution at
position 166 resulted in recognition (albeit weak) by DX9 but did
not significantly affect the affinity of Z27 Ab (Fig. 2C), demon-
strating the independent effects of these two positions on DX9 and
Z27 reactivity. As KIR3DS1 and several revertants do not show
any affinity for the DX9 Ab, regardless of good cell surface ex-
pression, the DX9 mean fluorescence intensity (MFI) expressed
relative to FLAG drops to less than one.
Position 199 contributes to the Z27 epitope
KIR3DS1 also contains a unique amino acid at position 199 in the
D2 domain, expressing a leucine in place of a proline residue.
Mutation of this residue in KIR3DS1 does not alter either cell
surface expression or DX9 reactivity but did abrogate recognition
by the Z27 Ab (Fig. 2D). This result is somewhat unexpected as
Z27 shows greater affinity for inhibitory allotypes (expressing
a proline at this position) than for KIR3DS1. However, in the
context of the KIR3DS1 sequence, the presence of proline at this
position completely abrogated recognition, suggesting that the
exact nature of the epitope recognized by Z27 differs between
inhibiting and activating forms of this 3D KIR. Indeed, when the
sequence was further altered to more closely resemble the se-
quence in inhibitory allotypes, with residue 138 also reverted, Z27
recognition was restored to a level greater than that seen with
native KIR3DS1 sequence but less than that seen with single
mutation of position 138 (Fig. 2D). The double 138+199 variant
was also recognized by DX9, showing that whereas substitution at
either 138 or 199 alone was not sufficient to generate a protein
recognized by DX9, the combination of these two positions results
in Ab recognition. Notably, the *054 allotype, which is identical to
KIR3DS1 in the D1 domain (including W138) but contains
a proline at position 199, is recognized, albeit weakly, by DX9.
*054 differs from KIR3DS1 at several positions both in the D0
and D2 domains, implicating at least one of these residues in the
generation of the DX9 epitope.
Single amino acid substitutions in D1 of KIR3DL1 abrogate
HLA binding
HLA-Bw4 binding has been detected with all tested inhibitory
KIR3DL1 subtypes; binding to KIR3DS1, however, cannot be
observed under similar conditions. This mirrors the reactivity seen
with the DX9 Ab suggesting that the key amino acids involved in
Table I. Mutagenesis primers: primer sequences used for the mutagenesis of KIR3DL1 and KIR3DS1
constructs
Change
Primer Sequence (Forward and Reverse)a
(59 to 39)KIR Allotype Amino Acid Nucleotide
KIR3DL1*01502 G138W G475T CTGCACAAAGAGTGGATCTCTAAGGACCCC
GGGGTCCTTAGAGATCCACTCTTTGTGCAG
P163S C550T CAATTTCTCCATCGGTTCCATGATGCTTGCCC
GGGCAAGCATCATGGAACCGATGGAGAAATTG
L166R T560G CGGTCCCATGATGCGTGCCCTTGCAGGG
CCCTGCAAGGGCACGCATCATGGGACCG
KIR3DS1 W138G T475G CTGCACAAAGAGGGGATCTCTAAGGACCCC
GGGGTCCTTAGAGATCCCCTCTTTGTGCAG
S163P T550C CAATTTCTCCATCGGTCCCATGATGCGTGCCC
GGGCACGCATCATGGGACCGATGGAGAAATTG
R166L G560T CGGTTCCATGATGCTTGCCCTTGCAGGG
CCCTGCAAGGGCAAGCATCATGGAACCG
L199P T659C CATCGTGGTCACAGGTCCATATGAGAAACCTTCTC
GAGAAGGTTTCTCATATGGACCTGTGACCACGATG
KIR3DS1_S163P R166L G560T GGTCCCATGATGCTTGCCCTTGCAGGG
CCCTGCAAGGGCAAGCATCATGGGACC
aThe forward sequence is given in the first row and the reverse sequence in the second row of the respective table cell for
each primer.
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both Ab and HLA recognition are the same. To test this possibility,
we examined the ability of 3DL1*01502 constructs to bind to
HLA tetramers, including two HLA-Bw4 tetramers (B*2705 and
A*2402). Expression of 3DL1*01502 in HEK293T cells was
found to lead to binding of Bw4 tetramers (Fig. 3A), which could
be inhibited by blocking with the Z27 Ab (data not shown).
Binding to the Bw6 tetramer B*0801 was used as a negative
control. Substitution at position 138 (G138W) dramatically re-
duced the binding of KIR3DL1 to the tested tetramers (Fig. 3B).
Similarly, mutation of position 166 also resulted in a loss of tet-
ramer binding, whereas single mutation of position 163 resulted in
a loss of binding to B*2705-SRHHAFLFR tetramer but only
FIGURE 1. Allelic variant *054 is poorly recognized by two anti-3DL1 Abs despite maintained cell surface expression. A, A comparison of selected
KIR3DL1 and KIR3DS1 allotypes at key D1 and D2 residues. B, HEK293T cells were transfected with 2 mg of plasmid containing FLAG-tagged
KIR3DL1*01502 (left panels) or KIR3DL1*054 (right panels) and stained with anti-FLAG and anti-KIR3DL1 DX9 (top panels) or Z27 (bottom panels)
Abs. C, HEK293T cells were transfected with increasing concentrations of plasmid expressing FLAG-tagged KIR3DL1*01502 (closed diamonds) or
KIR3DL1*054 (open circles) and stained with anti-FLAG Ab. D, HEK293T cells were transfected with increasing concentrations of plasmid expressing
FLAG-tagged KIR3DL1*01502 (closed squares) or KIR3DS1 (closed triangles) and stained with anti-FLAG Ab. MFI of FLAG was calculated by gating on
the FLAG-positive cells. The results are representative of findings made in at least two independent experiments.
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FIGURE 2. Allelic polymorphism in KIR3DL1 uncovers amino acid variations in D1 domain that differentially influences DX9 and Z27 recognition. A,
HEK293T cells were transfected with increasing concentration of plasmid expressing FLAG-tagged KIR3DL1*01502 (squares), KIR3DL1*054 (upright
triangle), or KIR3DL1*01502 G138W (inverted triangle) and stained with anti-FLAG, DX9, and Z27 Abs. TheMFI of the positive population is shown. B, As
for Awith plasmids containing FLAG-tagged KIR3DL1*01502 (squares), *01502 P163S (upright triangles), and *01502 L166R (inverted triangles). Data are
expressed as DX9 or Z27 MFI relative to the anti-FLAG MFI of the total cell population to normalize for variation in cell surface expression due to
transfection efficiency (e.g., for *01502 1 mg DNA: FLAG MFI 26, DX9 MFI 129, ratio 5.0). C, HEK293T cells were transfected with increasing con-
centration of plasmid expressing FLAG-tagged KIR3DS1 (closed squares), KIR3DS1 W138G (triangle), KIR3DS1 S163P (open squares), KIR3DS1 R166L
2166 KIR3DS1*014 BINDS TO HLA-Bw4
  
reduced the binding to A*2402-RYPLTFGW. Thus, it appears that
all three D1 residues that differ between KIR3DL1 and KIR3DS1
play a role in HLA recognition. As KIR3DL1*054 contains all
three of these substitutions (G138W, P163S, L166R), we predicted
that this allotype would not recognize HLA-Bw4, and indeed
binding to HLA-B*5701 was lost (data not shown).
Single amino acid reversion of position 138 of KIR3DS1
permits HLA binding
Mutation of *01502 suggests that all three 3DS1-specific D1
positions contribute to HLA binding, in particular positions 138
and 166. To examine the influence of these amino acid positions in
the context of the KIR3DS1 sequence, we expressed KIR3DS1
and single mutants in HEK293T cells and examined HLA re-
activity. Despite the evidence from KIR3DL1 that the presence of
glycine at position 138 and leucine at position 166 was necessary
for HLA recognition (Fig. 3), we found that KIR3DS1 with
a single substitution at position 138 was sufficient to confer HLA
binding. This binding is seen with both HLA-Bw4 tetramers A*24
and B*57, but specificity for HLA-Bw4 is maintained, as no
binding to the HLA-Bw6 tetramer B*08 was detected (Fig. 4A).
KIR3DS1 transfectants did not bind to any of the tested tetramers
(data not shown). The binding to both HLA-A*24 and HLA-B*57
could be blocked by preincubation with the Z27 Ab. Single re-
version of either 163 or 166 in KIR3DS1 was not sufficient to
allow tetramer binding (data not shown).
FIGURE 3. Single amino acid substitutions in the
D1 domain of KIR3DL1 abrogate HLA binding. A,
HEK293T cells were transfected with 2 mg of plasmid
containing FLAG-tagged KIR3DL1*01502, *01502
G138W, *01502 P163S, and *01502 L166R and
stained with PE-conjugated HLA tetramers. Dashed
line represents staining with HLA-A*2402 (left pan-
els) or HLA-B*2705 (right panels), and solid line re-
presents staining with control HLA-B*0801. B, The
MFI of the tetramer-stained cells is expressed as fold
change over the fluorescence of unstained cells. Data
shown are the averages of two independent experi-
ments; error bars represent SD.
(diamonds), or KIR3DS1 L199P (circles) and analyzed as in A.D, A comparison of the staining profile of transfected HEK293T cells stained with anti-FLAG
and DX9 (top panels) and Z27 (bottom panels) Abs. Results are representative of findings made in at least two independent experiments.
The Journal of Immunology 2167
  
To confirm the recognition of HLA-Bw4 by KIR3DS1 W138G,
we tested the interaction using a chimeric reporter assay. Jurkat
cells stably expressing KIR3DS1 or KIR3DS1 W138G as chimeric
receptors with CD3 z-chain were stimulated with 721.221 cell
lines expressing HLA-B*5701 or HLA-B*5801 (both Bw480I
allotypes). Although both KIR3DS1 cell lines responded with
a clear increase in NFAT upon stimulation with plate-bound Z27
Ab, only KIR3DS1 W138G showed recognition of HLA-Bw4
(Fig. 4B).
Complex interaction of 3DS1-specific residues combine to
control HLA recognition
Mutation of position 138 in KIR3DS1 (tryptophan to glycine)
resulted in increased affinity of the Z27 Ab; however, reverting both
138 and 199 together reduced the affinity back to baseline (Fig.
2D). This suggests that the interaction of these amino acid resi-
dues in the D1 and D2 domains of the protein determine Ab re-
activity, at least in part. To address the possibility that this was
also true for HLA binding, we generated a panel of KIR3DS1
mutations in which combinations of positions 138, 163, 166, and
199 were reverted to the residue found in KIR3DL1. These con-
structs were transfected into the HEK293T cells, and their ability
to bind Bw4 tetramers was examined as before. Reversion of
W138G alone was sufficient to allow tetramer binding, and com-
bining this with reversion of position 166 (arginine to leucine)
gave similar levels of binding (Fig. 5A). The combination of 138
and 163 resulted in increased tetramer staining, despite the dom-
inant role of position 166 in KIR3DL1 binding. Notably, when
reversion of position 138 was combined with position 199 (leucine
to proline), HLA reactivity was lost (Fig. 5A). Triple revertants of
138+199 with either 163 or 166 similarly gave no HLA reactivity.
Only when all the residues in the cluster were reverted to the
KIR3DL1 sequence was HLA binding restored in the presence of
proline 199 (Fig. 5B).
Discussion
KIR3DL1 is a highly polymorphic KIR with greater than 60 alleles
described to date. Allotypic variation is known to influence the
pattern of Ab reactivity, HLA-Bw4 binding characteristics, and
peptide specificity of these KIR3DL1 variants. The KIR3DL1
allele *054 is identical to the common *002 allele at all positions
except those in exon 4, where it is identical to KIR3DS1. This new
allele is likely to have arisen by a gene conversion event where
exon swapping between an existing KIR3DL1 allele (*002) and
KIR3DS1 occurred. In our previous study, we identified this allele
in only one person of Hispanic origin (2), and there are no addi-
tional reports in the ImMunoGeneTics database. We have pre-
viously shown that NK cells from a *054 donor display a very-
low-intensity staining profile with an anti-KIR3DL1 Ab, which
suggested that this allotype may be expressed at a low level on the
cell surface, possibly due to intracellular retention as has been
FIGURE 4. Reversion of W138 of KIR3DS1 to the G138 of KIR3DL1
allows binding of HLA. A, HEK293T cells were transfected with 2 mg
of plasmid containing FLAG-tagged KIR3DS1 W138G and stained with
PE-conjugated HLA tetramers. Cells were preincubated with Z27 or
mouse IgG1 (10 mg/ml) for 10 min prior to staining. B, Jurkat cell lines
expressing KIR3DS1*013 or KIR3DS1*014 extracellular domain fused
to the CD3 z-chain were stimulated with Z27 Ab or 721.221 cell line
transfectants at a 1:1 stimulator to responder ratio. Luciferase activity
was measured after 18 h as a measure of NFAT activity and normal-
ized to unstimulated control. Data shown are representative of n = 2
(KIR3DS1*013) or n = 4 (KIR3DS1*014) independent experiments.
FIGURE 5. Complex interaction of KIR3DS1-specific residues combine
to control HLA recognition. HEK293T cells were transfected with 2 mg of
plasmid containing FLAG-tagged KIR3DS1 or the indicated double (A),
triple, or quadruple mutant (B) and stained with PE-conjugated HLA tet-
ramers. The MFI of the tetramer-stained cells is expressed as fold change
over the fluorescence of unstained cells. Data shown are the averages of
two independent experiments; error bars represent SD.
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shown for other allotypes (2). However, we have shown in this
study that the *054 allotype is well expressed at the cell surface
and that the dim staining profile is a reflection of reduced
Ab affinity. This is similar to the poor recognition by Z27 of
KIR3DS1, which our findings in this study show is also well
expressed at the cell surface. Much of the reduced recognition of
*054 relative to *01502 is due to the dramatic amino acid change
at position 138, from the small glycine residue to the bulky
tryptophan, which considerably reduced the affinity of both Ab
clones. Although the staining pattern of DX9 mirrors that of Z27
for inhibitory KIR3DL1 allotypes, it has been appreciated that the
exact epitopes for these two Abs differ with mutation at residue
200 playing a role in the DX9 but not the Z27 recognition (30). In
this study, we identify a role for position 138 in both Ab epitopes,
whereas DX9 is more heavily dependent on position 166 and Z27
on position 163. Sharma et al. (25) reported similar results for
the role of positions 163 and 166 in a mutagenesis study of
KIR3DL1*015 but failed to detect any effect of position 138.
Although this discrepancy is puzzling, the role of position 138 in
both the DX9 and Z27 epitope is further supported in the analysis
of 3DS1 mutants in which single residues were reverted to those
found in KIR3DL1 allotypes. Notably, although in the context of
KIR3DS1 positions 138 and 199 cooperate to form a DX9 epitope,
the double revertant showed weaker Z27 staining than that seen
with the single 138. This is surprising given that KIR3DL1 allo-
types that are well recognized by Z27 have these residues at
positions 138 and 199, highlighting the role of positions 163 and
166 in the formation of the binding face. Thus the variation among
donors in the profile of Ab staining of KIR3DL1 is attributable to
allelic polymorphism leading to variation in the frequency of gene
expression (31), mature protein at the cell surface (26, 27), as well
as variation in Ab affinity.
In addition to the difference seen between KIR3DL1 and
KIR3DS1 in Ab affinity, the more relevant difference in these
molecules is the lack of HLA binding to KIR3DS1. Our analysis of
KIR3DL1*01502 suggests that, similar to the DX9 epitope, the
key residues involved in HLA recognition are 138 and 166, with
a lesser role for 163. Single mutation of either 138 or 166 com-
pletely abrogated binding to two different Bw4 tetramers, and
mutation of position 163 led to the loss of binding to B*2705 and
a reduction in A*2402 binding. The critical individual role of
these multiple D1 variants suggests that the rare KIR3DL1 allo-
type *054, which varies from all other 3DL1 allotypes at these
three positions, would not be capable of binding HLA-Bw4. In-
deed, this proved to be the case, as no binding was detectable to
HLA-B*57 tetramer (data not shown). This rare allotype is likely
to represent a recently arisen variant of KIR3DL1, generated via
an exon 4 swap with KIR3DS1 that shares with KIR3DS1 a lack
of broad HLA-Bw4 reactivity. It differs from KIR3DS1 in the
potential HLA binding face in possessing proline rather than
leucine at position 199 (encoded by exon 5). Based on the evi-
dence we present in this article that position 199 cooperates with
the residues of D1 to determine HLA binding, we predict that
*054 will not share the (as yet undefined) specificity of KIR3DS1.
Rather, KIR3DL1*054 may represent a KIR3DL1 allotype with
no affinity for HLA-Bw4, although more extensive analysis would
be required to confirm this.
Analysis of the D1 dimorphic residues in the context of
KIR3DL1 binding to HLA-Bw4 suggests than any one of D1
changes could be responsible for the lack of detectable HLA
binding by KIR3DS1. It was therefore unexpected when reversion
of position 138 alone in KIR3DS1 allowed binding to HLA. This
variant of KIR3DS1 bound to both A*2402 and B*5701 (both Bw4
80I molecules) but not B*2705 (Bw4 80T) tetramer. This is of
particular interest because an allotype of KIR3DS1 (3DS1*014)
has been described that carries a glycine in place of tryptophan at
this position (32, 33). Thus, we have characterized KIR3DS1*014
as an activating 3D receptor with the potential for robust re-
cognition of multiple Bw4 allotypes. Phylogenetic analysis of
KIR3DL1 and KIR3DS1 sequences by Norman et al. (33) reveals
that the extracellular domains of KIR3DS1 lineage diverged from
KIR3DL1 lineages .3.9 million years ago. This analysis suggests
that KIR3DS1*014 arose earlier than KIR3DS1*013 and likely
represents an intermediate between the ancestral HLA-binding
inhibitory receptors and KIR3DS1*013. KIR3DS1*013 was sub-
sequently subject to positive selection and now represents the
overwhelming majority of KIR3DS1 sequences globally. This
suggests that there was a strong evolutionary pressure to main-
tain the KIR3DS1*013 allotype with its restricted Bw4 recogni-
tion rather than an activating KIR3DS1*014 with broad Bw4
specificity.
KIR3DS1*014 has been reported in only three populations
(English, Tanzanian, and Nigerian) and here only at low allele
frequency (0.003, 0.006, and 0.003, respectively). Notably, two of
these populations are African, which shows a higher frequency of
HLA-Bw4 carriage (and in particular HLA-Bw4 80I) (34), which,
as we show in this study, acts as a ligand for this receptor. It is
therefore attractive to speculate that this activating receptor may
have in the past provided a selective advantage in these regions,
where, for example, high ligand frequency and unique environ-
ment of pathogens may have allowed those individuals with
KIR3DS1*014 to mount a more effective immune response. The
low frequency of this receptor that is now present in these pop-
ulations may therefore represent a move toward loss of this acti-
vating receptor in the absence of that selective pressure, a feature
seen in the evolution of other activating KIRs (discussed later).
The lack of a well-defined ligand for KIR3DS1*013 remains
a significant challenge in the field. The ability to detect evidence
of an interaction of KIR3DS1 with HLA-Bw4 only in the presence
of HIV infection suggests that this recognition may be controlled
at the level of peptide presented. Alternatively, factors including
the level of HLA class I expression and the presence of additional
cofactors or coreceptors may determine the nature of the in-
teraction. Among other members of the KIR family, KIR3DL2
shows a strong dependence on the presented peptide, with bind-
ing to A*3 and A*11 appearing to rely on the presence of EBV-
derived sequences (6). The interaction of KIR2DS1 with HLA-
C2 is influenced by the level of HLA expression, with binding
seen only after an increase in expression as a consequence of
EBV infection (9).
The low-affinity interaction of the KIR2DS molecules with their
HLA-C ligands has been mapped to specific amino acid residues
in the extracellular domain that differ from those found in the
inhibitory counterparts. For KIR2DS1, this difference in binding
affinity was mapped to position 70 of the KIR molecule, with
substitution of the threonine of 2DL1 for the lysine of 2DS1
diminishing the binding of the long-tailed KIR (35). Similarly, the
binding of 2DS2 to HLA-C is of much lower affinity than that
of the corresponding inhibitory KIR (2DL2/3). This receptor dif-
fers from KIR2DL2/3 by only 4 aa in the extracellular domain—
substitution at position 45 (a tyrosine in 2DS2) for phenylalanine
was found to enhance the affinity of the 2DS KIR for HLA-C
ligand (10, 11). The restriction of HLA binding of KIR2DS4
(which recognizes some C1 and C2 allotypes as well as A*11) has
been attributed to a gene conversion event with KIR3DL2 that
resulted in a reduction of affinity of the parental molecule for
HLA-C (36). Thus, it appears that a common event in the evolu-
tion of the activating KIRs from their older inhibitory counterparts
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is the introduction of specific amino acid changes that result in
a reduction in affinity for HLA. In contrast, for KIR3DS1 there
are at least 4 aa changes, over two different exons, which could
be responsible for the lack of broad HLA binding by KIR3DS1.
Although analysis of single changes to the *01502 protein sug-
gests that any one of these changes could be responsible for the
“tuning down” of KIR3DS1 binding, the presence of additional
variant positions that impact HLA recognition suggests that the
driving force by which KIR3DS1 was generated from KIR3DL1
may differ from that of the HLA-C recognizing 2D KIR. Studies
of KIR3DS1 revertants in which combinations of two or more of
these variant positions are mutated suggest that the role of in-
dividual amino acids in the recognition of HLA by KIR3DS1 may
also differ from KIR3DL1. Thus, whereas proline at 199 appears
to be necessary for KIR3DL1 recognition of HLA (25), it prevents
HLA binding by KIR3DS1 W138G mutants. One intriguing in-
terpretation of these data is that the HLA recognition by KIR3DS1
does not simply mirror that of KIR3DL1 but with lower affinity,
as is the case of KIR2DS1 and KIR2DS2. Rather, the additional
amino acid changes may reflect a reprogramming or restriction of
the affinity for HLA-Bw4 thereby limiting reactivity. Analysis of
the evolution of activating KIRs from their inhibitory KIRs sug-
gests that this is a recurrent process with cycles of gain and loss
in the absence of a strong, persistent evolutionary pressure to
maintain activating KIRs (37). This is consistent with data from
disease association studies that suggest a protective role of acti-
vating KIR under certain circumstances, including viral infection,
but a deleterious one under others (e.g., in autoimmune con-
ditions). Thus, for KIR3DS1, the presence of multiple functionally
important amino acid changes relative to KIR3DL1 may be the
result of multiple pressures on KIR3DS1 to preserve a protective
function while restricting reactivity to prevent unwanted host
damage that might be predicted with KIR3DS1*014. This is a
particularly important consideration in our understanding of the
role and evolution of activating KIRs, as well as in the search for
a functional interaction between KIR3DS1 and its ligand, given
the growing number of disease outcomes that are influenced by
the presence of the KIR3DS1 gene.
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